Company Overview and News

5
GameStop Must Eliminate Its Dividend Or Suffer Blockbuster's Fate

2018-10-03 seekingalpha
On a 3,700-mile trip, I saw a lot of America, some good, some bad, some great, some depressing.
SSDIY NLS GME

2
Micron Investors: Be Happy About The Share Price Decline

2018-09-11 seekingalpha - 1
Micron's share price has declined due to negative analyst comments, but analysts have a history of being wrong regarding Micron's profitability.
SSDIY SSNNF SSNLF HXSCF AMAT AAPL HXSCL

1
Why I Believe Highpower International Revenues Should Surprise In The Coming Year

2018-07-30 seekingalpha - 1
Electric vehicles and smartphones should keep the demand for lithium batteries high for the next 15 years.
SSDIY DQ CALB HPJ

 
Global X Lithium ETF: Is The 20% Drop Warranted?

2018-07-19 seekingalpha
The Global X Lithium ETF (LIT), which consists of lithium miners and lithium-ion battery manufacturers, has been a favorite among investors looking to get exposure to electric vehicles and energy storage. After a stellar 2017, the ETF has given back some of its earlier gains. LIT is down 20% from its early January high.
SSDIY GALXF GXY 6674 MS GYUAF

36
AT&T Vs. Verizon: 2 Telecom Giants, 1 Surprising Winner

2018-07-19 seekingalpha - 1
AT&T (T) and Verizon (VZ) are the two biggest telecommunications companies in the US. In the recent past the two companies have taken different paths towards reshaping their business models. AT&T has expanded into content via its acquisition of Time Warner, Verizon is more focused on technological improvement.
SSDIY S TWX TWC

36
AT&T Vs Verizon: Two Telecom Giants, One Surprising Winner

2018-07-19 seekingalpha - 1
AT&T (T) and Verizon (VZ) are the two biggest telecommunications companies in the US. In the recent past the two companies have taken different paths towards reshaping their business models. AT&T has expanded into content via its acquisition of Time Warner, Verizon is more focused on technological improvement.
SSDIY S TWX TWC

68
Sonos IPO: Patented Technology And 10% Revenue Growth In 2017

2018-07-10 seekingalpha - 1
Experts estimate that global paid subscribers to streaming music services will grow from 176 million in 2017 to 293 million by 2021.
KKR P GOOG SNEJF SSDIY GS AMZN SPOT AAPL JEF SNE MS

8
Fossil: Classic Case Of Too Far, Too Fast

2018-06-25 seekingalpha
Shorts got greedy on Fossil in 2017, with resulting short covering driving a large portion of recent price appreciation.
SSDIY CHOO SWGNF SWGAY SWGAF KATE JYMHF

 
Will Posco Substitute For LG Chem In A New Offtake Agreement With Pilbara Minerals?

2018-05-30 seekingalpha
In a recent contribution, I introduced some doubts as to the possibility for LG Chem to convert Pilbara’s lithium concentrates into lithium carbonate or hydroxide in South Korea.
SSDIY PLS PILBF AGO ATLGF AGODY PKX

44
Global Battery Production Capacity Must Grow 21 Times To Electrify The Global Vehicle Fleet

2018-04-24 seekingalpha
An estimated battery manufacturing capacity of 6600 gigawatt-hours per year would be needed to electrify the global vehicle fleet.
SSDIY PCRFY TSLA

42
Lithium Investing: Capital Continues To Flow Into Lithium Assets As Demand Rises

2018-04-16 seekingalpha - 2
Battery production continues to climb as automakers bring new options to market; new energy vehicle sales figures continue to rise.
PILBF SSNLF ALB TYHOF LACDF 2333 NMKEF GALXF GCPEY ALTAF NMX OROCF EGT MLNLF EGTYF LAC PLS PCRFY GCPEF GWLLY SSDIY GXY 8015 PKXFF AJM STGYF

48
Lithium Junior Miner News For The Month Of March 2018

2018-03-28 seekingalpha - 1
Lithium spot and contract price news - Lithium spot prices moved sideways, whilst 2018 global LCE contract prices are up about 20%.
LIT SAV LAXXF LIACF PFFOF WML POR ABEPF SQM MLNLF VLKAY AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM AVL ALB DMNXF NMKEF LKE MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF PLS MSB DJI SSDIY PDDTF NTTHF AVLIF ORE AVZ AJM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 796054203